TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05485623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseNmore FC
Description: Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseNmore FC
Description: Pulsenmore Ltd. has developed a small portable vaginal ultrasound device for personal use at home. The ultrasound device allows to scan and assess both the uterus and the ovaries. This ultrasound device connects to a smartphone and a user-friendly application simplifies its use. This ultrasound device is based on the company's 'Pulsenmore ES ultrasound system' which is a small abdominal ultrasound device for home and self-use by pregnant women. This (abdominal) ultrasound device allows scanning and detection of fetal pulse, count fetal movements, assess the amount of amniotic fluid and more. The device is an abdominal ultrasound probe that connects to a smartphone using a specially designed socket. The main difference between the devices is the different design of the ultrasound vaginal probe.~The device consists of 2 components: a cradle and an application (software). The cradle contains the electronic components and the ultrasound probe.
Study: NCT06256263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total laryngectomy
Description: pharyngeal repair after total laryngectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total laryngectomy
Description: pharyngeal repair after total laryngectomy
Study: NCT05496556

Intervention type: OTHER
Group type: OTHER
Intervention: Test Leeds Food Preference Questionnaire (LFQP-France)
Description: The version of this questionnaire has been adapted to French eating habits. and based on the presentation of food photos, each representing one of the four categories below : salty-high in fat / salty-low fat / sugary-high fat / sweet-low fat The answers given to the LFQP predict a more or less caloric food intake. This tool makes it possible to objectify changes in eating behavior according to the nutritional status and protein status of patients.~The implied wanting score for salty-high-fat, salty-low-fat, sweet-high-fat, and sweet-low-fat foods is calculated based on the frequency and speed of choice for one food type out of 150 combinations.~For each of the food modalities, the software will return a score with its standard deviation. The modality preferred by the patient is the one with the highest score
Study: NCT05248477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premex Protocol
Description: This protocol presupposes stages during which staff are informed and trained. It is based on the following principles:~* Administration of corticosteroid therapy to all eligible women, independent of the decision about active or palliative care~* A prognostic evaluation in a non-emergency meeting of the obstetricians and neonatologists/pediatricians involved, no longer based only on gestational age, and enabling the team to provide consistent, consensual, and individualized information to parents;~* A joint decision about the obstetric and neonatal (active or palliative) care to be proposed to parents at the end of this evaluation;~* An interview with parents, also on non-emergency basis, to give them information about the child's prognosis and the management proposed, to answer their questions, and to obtain their opinion;~* Management at birth consistent with that decided in consultation with the parents.
Study: NCT05767827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, lidocaine with adrenaline
Description: Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, ropivacaine, lidocaine with adrenaline
Description: Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
Study: NCT05042284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-enteric coated pancreatic enzyme preparation
Description: The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-enteric coated pancreatic enzyme preparation
Description: The patients will be given a non-enteric coated pancreatic enzyme capsule containing 30000 U of protease thrice daily along with meals for 3 months.
Study: NCT06358144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packaging imagery
Description: Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packaging imagery
Description: Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.
Study: NCT05217004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLEAR Dementia Care mobile application
Description: The app provides information about dementia (e.g., types and symptoms of dementia) and allows caregivers to record, monitor, and chart behaviors in the care recipient.
Study: NCT06358144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packaging imagery
Description: Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Packaging imagery
Description: Participants in the four intervention conditions will be shown four cannabis edibles packages that have been altered to contain one of the imagery themes. All participants will see the same four products, and each condition will see the products with the same imagery theme.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Imagery (Control)
Description: Participants in the control condition will see the same four product packages, but without any added imagery.
Study: NCT06083298

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: patients will be operated under general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCP group
Description: patients will receive ultrasound-guided MCP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISP group
Description: patients will receive ultrasound-guided ISP block with 15 ml of bupivacaine 0.25% on each side followed by general anesthesia.
Study: NCT06246409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modernized patient instructions
Description: Patients will be given modernized patient instructions prior to radiotherapy treatment.
Study: NCT06034249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based VR
Description: Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Audio
Description: The mindfulness-based audio files for six weeks.
Study: NCT05228483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser
Description: CO2 fraction laser

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA) with red light illumination
Description: 5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate (MMF) 0.1% ointment
Description: 0.1% Mometasone furoate ointment is a potent steroid and has been proven to result as efficacious and well tolerated as clobetasol propionate which represent the recomended first-line treatment of vulvar lichen sclerosus.
Study: NCT05669872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose 50Mg/Ml Inj 20Ml
Description: ferric carboxymaltose 1000mg, fixed dose for intervention group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBC
Description: pack RBC transfusion
Study: NCT05293626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NR082 Injection
Description: The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection needle
Description: 19G 1 1/2IN TW filter needle with filter element (BD 305200)，used to NR082 Intraocular injection solution dose preparation; 30G 1/2IN injection needle (BD 305106)，used to NR082 Intraocular injection solution administration;~1 ml screw top syringe (BD 309628),used to NR082 Intraocular injection solution dose preparation and administration.
Study: NCT06503380

Intervention type: OTHER
Intervention: No intervenrion.
Description: This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
Study: NCT06584474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin neubilization
Description: nebulized azithromycin (Xithrone, Amoun, Egypt) that will be initiated from day 7 of birth in a dose of 20 mg/kg/day in two divided doses for 3 weeks till the time of primary outcome assessment (at 28 days of age). Azithromycin solution for nebulization will be prepared from intravenous vials containing 500 mg lyophilized powder. First, each lyophilized powder vial will be prepared with 5 ml normal saline according to the manufacturer's instruction. The reconstituted solution will be diluted with 28.5 ml normal saline to make a final concentration of 17.5 mg/ml according to clinical pharmacy recommendation. For nebulization of azithromycin, 0.6 ml of final drug prepared solution will be taken for every~1 kg body weight of patient, then made up to 3 ml of normal saline and will be administered by Aerogen Jet Nebulizer every 12 hours using 8 liter/min of medical air or by face mask if not mechanically ventilated. According to the manufacturer's declaration, prepared azithro

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: Device A mobile device (PHILIPS ® HD11 XE) with a 10-MHz linear probe will be used for chest ultrasound. It will be done at day 14 of postnatal life.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lung ultrasound
Description: Device A mobile device (PHILIPS ® HD11 XE) with a 10-MHz linear probe will be used for chest ultrasound. It will be done at day 14 of postnatal life.
Study: NCT05603598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAP-2 Protein, Human
Description: Intravenous infusion, mixed meal test, ad libitum meal test

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEAP-2 Protein, Human
Description: Intravenous infusion, mixed meal test, ad libitum meal test
Study: NCT04785924

Intervention type: DRUG
Group type: OTHER
Intervention: Imipenem+Relebactam
Description: Antibiotic treatment for KPC producing CRE-containing gram-negative infections
Study: NCT06246409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing patient instructions
Description: Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
Study: NCT05728138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus CBT
Description: Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
Study: NCT05937789

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Dose of vitamin D3 depends on participant's serum 25(OH)D levels, with one sample bottle contains 72,000 IU of vitamin D3; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
Study: NCT04734730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study: NCT05937789

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglycerides (MCT)
Description: Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglycerides (MCT)
Description: Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Medium Chain Triglycerides (MCT)
Description: Dose of MCT depends on participant's serum 25(OH)D levels, with one sample bottle contains 5 cc. of MCT; Intervention starts on ICU day 3 with a frequency of 1 ampule every 3 hours and is completed within the following 48 hours
Study: NCT04734730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT05541445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
Study: NCT05792917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafolecimab (a modified manufacturing process)
Description: 450mg，SC，single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tafolecimab (a original manufacturing process)
Description: 450mg，SC，single dose
Study: NCT05354687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small-group Teaching
Description: The Small-group Teaching will include theoretical lectures and laboratory practice. Theoretical training will be given in 2 hours and will last 2 week. After the theoretical training, laboratory practice will be made with mannequins, pressure injury models and photographs in the nursing skills laboratory. Laboratory practices will be done in groups of about 10 students. Laboratory application will take 1 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-directed Learning
Description: The training will be given in two stages. The first stage of the training will be given via the mobile application for 2 weeks. Students will be able to access the training individually, wherever and whenever they want, via the mobile application. In the second stage, students will individually conduct laboratory practice. Students who start using the mobile application will make laboratory applications individually, whenever they want when the laboratory is available. Models and materials that students will need will be available in the laboratory. They will be able to get help from the trainer when they need it. Individual laboratory application will take 1 week.
Study: NCT05688488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C
Description: Mitomycin-C was applied to both wound sites of bilateral vocal cords. After evenly applied, gently massage the applied site for 3-5 minutes until the drug was fully absorbed.
Study: NCT05006027

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention via the distal radial approach
Description: Percutaneous coronary intervention using a 7-Fr thin walled sheath (Prelude IDeal, MERIT MEDICAL, South Jordan, UT, USA) via the distal radial approach
Study: NCT06437470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction technique
Description: All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: blood flow restriction technique
Description: All participants in the control group will receive the conventional physical therapy program with the use non-inflated cuff as a sham treatment during exercising.~All participants in the intervention group will receive the conventional physical therapy program combined to blood flow restriction to 80% of limb occlusive pressure by using blood flow restriction cuff.
Study: NCT06343909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip abductor strengthening exercise
Description: in this group 15 participants will perform hip abductor streghtning along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 reputations will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intrinsic foot muscle strengthening along with conventional exercises
Description: in this group 15 participants will perform Intrinsic foot muscle strengthening along with conventional exercises .protocol for 8 weeks 24 sessions (3 sessions in a weak) and 10 sec rest between each segment,3 sets and 10 repitations will be performed.
Study: NCT05521789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESB Thoracic
Description: Erector spinae thoracic block with bupivacaine
Study: NCT05644704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower extremity and core muscle training
Description: Lower extremity training: single leg balance training Core muscle training: pelvic control training
Study: NCT06300164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unripre Carob
Description: The standard cookies and test cookies (with carob addition) to be used in the study will be produced by Dr. Lecturer Özlem ÖZPAK AKKUŞ at Toros University Nutrition Principles Laboratory. Prof. Dr. Özlem ÖZPAK AKKUŞ will produce the cookies. For standard cookies, 1 egg, 325 g gluten-free flour (Söke flour), 75 grams butter, 50 grams sugar, 10 grams baking powder, 10 grams vanilla will be added and the prepared bread mixture will be divided into 50 equal parts. To make cookies with the addition of unripe carob, the same recipe as the standard cookie will be used to make the test cookie with the addition of unripe carob fruit flour, divided into 50 equal parts, and the amount of unripe carob fruit flour will be added by calculating the daily fiber consumption amount of the patients participating in the study to be 25 g.